TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)
Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –
TG Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
TG Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 82.4%. For fiscal 2025 it was 83.7%, against 88.3% the year before. The highest annual figure on record is 94.0% in fiscal 2023.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.7% | −4.6 |
| FY2024 | Dec 31, 2024 | 88.3% | −5.7 |
| FY2023 | Dec 31, 2023 | 94.0% | +3.5 |
| FY2022 | Dec 31, 2022 | 90.5% | +2.3 |
| FY2021 | Dec 31, 2021 | 88.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 82.9% | −3.7 |
| Q1 FY2026 | Mar 31, 2026 | 83.6% | −3.5 |
| Q4 FY2025 | Dec 31, 2025 | 80.2% | −5.6 |
| Q3 FY2025 | Sep 30, 2025 | 82.6% | −6.2 |
| Q2 FY2025 | Jun 30, 2025 | 86.6% | −2.1 |
| Q1 FY2025 | Mar 31, 2025 | 87.1% | −4.3 |
| Q4 FY2024 | Dec 31, 2024 | 85.8% | +3.6 |
| Q3 FY2024 | Sep 30, 2024 | 88.9% | −9.0 |
| Q2 FY2024 | Jun 30, 2024 | 88.7% | +0.6 |
| Q1 FY2024 | Mar 31, 2024 | 91.4% | +2.4 |
| Q4 FY2023 | Dec 31, 2023 | 82.1% | −14.1 |
| Q3 FY2023 | Sep 30, 2023 | 97.9% | +0.0 |
| Q2 FY2023 | Jun 30, 2023 | 88.1% | +5.6 |
| Q1 FY2023 | Mar 31, 2023 | 89.0% | – |
| Q4 FY2022 | Dec 31, 2022 | 96.3% | – |
| Q3 FY2022 | Sep 30, 2022 | 97.9% | – |
| Q1 FY2021 | Mar 31, 2021 | 82.5% | – |
See a number that looks wrong?